Diagnostic characteristics of 280 adult patients with ALL
| Parameter . | No. of cases . | ||
|---|---|---|---|
| Evaluable . | Positive (%) . | Median (range) . | |
| Age, y | 280 | 38 (16-66) | |
| Male sex, no. | 154 (55) | ||
| Hemoglobin, g/L | 98 (24-165) | ||
| WBC, ×109/L | 16.5 (0.6-900) | ||
| Blast count, ×109/L | 7.4 (0-855) | ||
| Bone marrow blasts, % | 90 (25-100) | ||
| Platelets, ×109/L | 45 (4-420) | ||
| Hepatomegaly, no. | 277 | 80 (28.8) | |
| Splenomegaly, no. | 275 | 115 (41.8) | |
| Lymphadenopathy, no. | 277 | 81 (29.2) | |
| CNS involvement, no. | 274 | 13 (4.7) | |
| FAB morphology, no. | 270 | ||
| L1 | 76 (28.1) | ||
| L2 | 194 (71.9) | ||
| EGIL immunophenotype, no. | 280 | ||
| B-I/pro-B | 44 (16) | ||
| B-II/common | 129 (46) | ||
| B-III/pre-B | 43 (15.3) | ||
| TII/pre-T | 17 (6) | ||
| T-III/cortical | 31 (11) | ||
| T-IV/mature-T | 10 (3.6) | ||
| T-undefined | 6 (2.1) | ||
| Cytogenetics/molecular genetics, no.* | 276 | ||
| Adverse | |||
| t(9;22) and/or BCR-ABL | 68 (24.6) | ||
| t(4;11) and/or MLL-AF4 | 20 (7.3) | ||
| Other† | 19 (6.9) | ||
| Nonadverse | |||
| t(1;19) and/or E2A-PBX1 | 5 (1.8) | ||
| Hyperdiploid | 12 (4.3) | ||
| Other | 20 (7.3) | ||
| Normal | 84 (30.4) | ||
| Not known (cytogenetics) | 48 (17.4) | ||
| Clinical risk class, no. | 280 | ||
| SR B-precursor | 74 (26.4) | ||
| T-precursor | 22 (7.9) | ||
| HR B-precursor | 54 (19.3) | ||
| T-precursor | 37 (13.2) | ||
| VHR t(9;22)/BCR-ABL | 68 (24.3) | ||
| t(4;11)/MLL-AF4 | 20 (7.1) | ||
| Undefined (T cell) | 5 (1.8) | ||
| Parameter . | No. of cases . | ||
|---|---|---|---|
| Evaluable . | Positive (%) . | Median (range) . | |
| Age, y | 280 | 38 (16-66) | |
| Male sex, no. | 154 (55) | ||
| Hemoglobin, g/L | 98 (24-165) | ||
| WBC, ×109/L | 16.5 (0.6-900) | ||
| Blast count, ×109/L | 7.4 (0-855) | ||
| Bone marrow blasts, % | 90 (25-100) | ||
| Platelets, ×109/L | 45 (4-420) | ||
| Hepatomegaly, no. | 277 | 80 (28.8) | |
| Splenomegaly, no. | 275 | 115 (41.8) | |
| Lymphadenopathy, no. | 277 | 81 (29.2) | |
| CNS involvement, no. | 274 | 13 (4.7) | |
| FAB morphology, no. | 270 | ||
| L1 | 76 (28.1) | ||
| L2 | 194 (71.9) | ||
| EGIL immunophenotype, no. | 280 | ||
| B-I/pro-B | 44 (16) | ||
| B-II/common | 129 (46) | ||
| B-III/pre-B | 43 (15.3) | ||
| TII/pre-T | 17 (6) | ||
| T-III/cortical | 31 (11) | ||
| T-IV/mature-T | 10 (3.6) | ||
| T-undefined | 6 (2.1) | ||
| Cytogenetics/molecular genetics, no.* | 276 | ||
| Adverse | |||
| t(9;22) and/or BCR-ABL | 68 (24.6) | ||
| t(4;11) and/or MLL-AF4 | 20 (7.3) | ||
| Other† | 19 (6.9) | ||
| Nonadverse | |||
| t(1;19) and/or E2A-PBX1 | 5 (1.8) | ||
| Hyperdiploid | 12 (4.3) | ||
| Other | 20 (7.3) | ||
| Normal | 84 (30.4) | ||
| Not known (cytogenetics) | 48 (17.4) | ||
| Clinical risk class, no. | 280 | ||
| SR B-precursor | 74 (26.4) | ||
| T-precursor | 22 (7.9) | ||
| HR B-precursor | 54 (19.3) | ||
| T-precursor | 37 (13.2) | ||
| VHR t(9;22)/BCR-ABL | 68 (24.3) | ||
| t(4;11)/MLL-AF4 | 20 (7.1) | ||
| Undefined (T cell) | 5 (1.8) | ||